1 0

    FDA Bioequivalence Discipline Review for ANDA 210317 – Octreotide Acetate Injection (TEVA)

    FDA Bioequivalence Discipline Review for ANDA 210317 – Octreotide Acetate Injection (TEVA)

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request: Dear Sir/Madam, I would like to request Bioequivalence discipline review for Octreotide Acetate injectable;Injection- EQ 10mg Base/vial, EQ 20mg Base/vial and EQ 30mg Base/via. ANDA-210317, Applicant - TEVA PHARMS USA INC.
    Tags: Pharma, ANDA, 2025

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details